Mandate

Vinge advises Smart Eye AB in conjunction with its listing on Nasdaq First North

November 11, 2016

Vinge has advised Smart Eye AB in connection with the listing of Smart Eye’s shares on Nasdaq First North.

In connection with the listing, a new issue of not more than 1 750 000 shares was performed whereupon Smart Eye will receive not more than SEK 80 500 000. The offer is directed to the general public and institutional investors. The prospectus was published on 10 November and the first day of trading is 7 December.

Vinge’s team primarily consisted of responsible partner Anders Strid, Magnus Pauli (client relationship), Frida Bäckegren (project manager due diligence and prospectus), Joel Zetterström and Natalie Bäck (IP), Jonas Lindeblad (employment), Björn Nicolai and Karin Wisenius (EU and competition), Victor Ericsson (tax) and company assistant Camilla Andersson.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025